৳ 626.67/unit
Pack: ৳ 18,800.10
৳ 626.67/unit
Pack: ৳ 18,800.10
At a glance
Ceritinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.
Indications
- ALK-positive metastatic non-small cell lung cancer (NSCLC)
Pharmacology
Ceritinib is a kinase inhibitor. Targets of Ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, Ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK dependent cancer cells in in vitro and in vivo assays.
Dosage
Recommended Dose: 450 mg orally once daily with food until disease progression or unacceptable toxicity.
Hepatic Dose: Severe hepatic impairment (Child-Pugh C): Reduce dose by approximately one-third, rounded to the nearest multiple of the 150 mg dosage strength. No dose adjustment is recommended in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Side effects
Common Side Effects (≥10%):
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Elevated liver enzymes (ALT/AST)
- Hyperglycemia
- Bradycardia
- Pancreatitis
Serious Side Effects: Interstitial Lung Disease/Pneumonitis, QT Prolongation, Hepatotoxicity.
Use in pregnancy
Ceritinib can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Females of reproductive potential should use effective contraception during treatment and for 6 months following completion of therapy.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Gastrointestinal Reactions: Monitor and manage diarrhea, nausea, vomiting, or abdominal pain with standard care.
- Hepatotoxicity: Monitor liver function tests (ALT, AST, total bilirubin) once a month and as clinically indicated.
- Interstitial Lung Disease/Pneumonitis: Monitor for pulmonary symptoms.
- QT Prolongation: Avoid in congenital long QT syndrome; monitor with ECGs and electrolytes.
- Hyperglycemia: Monitor fasting serum glucose.
- Bradycardia: Regularly monitor heart rate and blood pressure.
- Pancreatitis: Monitor lipase and amylase.
- Embryo-Fetal Toxicity: Can cause fetal harm; advise effective contraception.
Overdose effects
Information on Ceritinib overdosage is not available. In case of overdose, general supportive measures should be instituted.
Storage conditions
Store below 30°C in a cool and dry place, away from sunlight. Keep out of reach of children.